Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

MLA

Ignatiadis, Michail, et al. “Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel Followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.” PloS One, vol. 11, no. 7, July 2016, p. e0154009. EBSCOhost, https://doi.org/10.1371/journal.pone.0154009.

APA

Ignatiadis, M., Zardavas, D., Lemort, M., Wilke, C., Vanderbeeken, M.-C., D’Hondt, V., De Azambuja, E., Gombos, A., Lebrun, F., Dal Lago, L., Bustin, F., Maetens, M., Ameye, L., Veys, I., Michiels, S., Paesmans, M., Larsimont, D., Sotiriou, C., Nogaret, J.-M., … Awada, A. (2016). Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. PloS One, 11(7), e0154009. https://doi.org/10.1371/journal.pone.0154009

Chicago

Ignatiadis, Michail, Dimitrios Zardavas, Marc Lemort, Celine Wilke, Marie-Catherine Vanderbeeken, Veronique D’Hondt, Evandro De Azambuja, et al. 2016. “Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel Followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.” PloS One 11 (7): e0154009. doi:10.1371/journal.pone.0154009.